- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05910554
Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis (MetforminTOP)
Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial
This is a double blinded, randomized, placebo controlled clinical trial of 40 participants with pulmonary sarcoidosis.
Primary Objective: To assess the steroid-sparing efficacy and safety of oral metformin therapy in participants with confirmed progressive pulmonary sarcoidosis for participants with steroid dependent disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to assess the efficacy of Metformin therapy in terms of steroid-sparing efficacy for sarcoidosis patients with steroid-dependent disease. Given that the morbidity and mortality has proven to be significant in patients with sarcoidosis, we believe there is unprecedented opportunity for improved clinical outcomes if the right interventional agent can be identified. In choosing steroid-sparing effect as the primary outcome, we will be able to detect changes in clinical outcomes that are important to patients and to the scientific community. We anticipate that these improvements will reduce or resolve the necessity of immunosuppressant therapy in these participants.
At least 40 participants will be randomized in equal proportion to metformin or placebo. Twenty completed participants per arm provide 80% power to reject (one-sided type I error of 5%) the null hypothesis that mean daily steroid use in the placebo treated group is less than in the metformin treated group using analysis of covariance adjusting for baseline average steroid use.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as defined by the clinical presentation consistent with sarcoidosis, as well as biopsy demonstrating granulomas, and no alternative for the cause of the granulomas, such as tuberculosis for at least one year prior to randomization. Tuberculosis must be ruled out by negative histology and culture.
- Patients must be symptomatic of pulmonary sarcoidosis with FVC 45-85%
- Steroid dosage of >10mg of prednisone for at least 6 months
Exclusion Criteria:
- Inability to obtain consent
- Age less than 18 years of age
- Female participants of childbearing potential not willing use one of the following methods of birth control for the duration of the study and 90 days after study completion: condoms, sponge, foams, jellies, diaphragm, or non-hormonal intrauterine device, a vasectomized sole partner or abstinence. Females of childbearing potential must have a negative urine pregnancy test at screening visit
- FVC predicted value is < 45%.
- Creatine clearance of <30%.
- History of idiopathic Lactate ≥ 2.2 mmol/L or acidosis on study baseline metabolic profile
- End-stage fibrotic pulmonary disease
- Significant underlying liver disease
- Allergy or intolerance to metformin
- Allergy or intolerance to albuterol
- Poor venous access for obtaining blood samples
- Significant disorder, other than sarcoidosis, that would complicate the treatment evaluation, such as respiratory, cardiac, renal, neurologic, musculoskeletal or seizure disorders.
- Use of an investigational drug within 30 days prior to screening or within 5 half-lives of the agent, whichever is longer.
- Currently receiving >40mg prednisone.
- ALT or AST ≥5 times upper limit of normal (ULN).
- Leukopenia, as defined by WBC <3.0 cells/mm3 or absolute neutrophil count <1000 mm3
- Breast feeding.
- If patient is on immunomodulators, they must be on regimen for ≥3-month period and on a stable dose for ≥ 4 weeks.
- Most recent nuclear medicine scan or echocardiogram (if done), demonstrating cardiac ejection fraction <35%
- Participant has persistent or active infections requiring hospitalization or treatment with antibiotics, antiretrovirals, or antifungals within 30 days of baseline. Minocycline and doxycycline are not considered antibiotics when used to treat sarcoidosis.
- Any significant finding in the patient's medical history or physical or psychiatric exam prior to or after randomization that, in the opinion of the investigator, would affect patient safety or compliance or ability to deliver the study drug according to protocol.
- On medications that, in the opinion of the investigator, would affect patient safety when taken with metformin
- History of or receiving treatment for pulmonary hypertension. Receiving biologic medication within the 6 months prior to screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active
Patients randomized to metformin will be assigned the active arm.
|
Patients randomized to metformin will be assigned the active arm.
Other Names:
|
Placebo Comparator: Placebo
Patients randomized to cellulose will be assigned the placebo arm.
|
Patients randomized to cellulose will be assigned the placebo arm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the steroid-sparing efficacy and safety of oral metformin therapy in patients with progressive pulmonary sarcoidosis.
Time Frame: 24 weeks
|
Mean daily oral corticosteroid dose post protocol-driven steroid taper at 24-weeks after randomization.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To compare cumulative total steroid use between those randomized to metformin or placebo
Time Frame: 24 weeks
|
• Average dose and cumulative total steroid use in the 24-week study horizon.
|
24 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00105681
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoidosis, Pulmonary
-
Celularity IncorporatedTerminatedStage 2 Pulmonary Sarcoidosis | Stage 3 Pulmonary SarcoidosisUnited States
-
University Hospital, LilleTerminated
-
Alexandria UniversityCompletedEndobronchial Mucosal Pathology in Pulmonary SarcoidosisEgypt
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedSarcoidosis; Antimycobacterial TherapyUnited States
-
National Jewish HealthAmerican Thoracic SocietyCompletedPulmonary SarcoidosisUnited States
-
Medical University of South CarolinaHoffmann-La RocheTerminated
-
University of Milano BicoccaAgenzia Italiana del FarmacoCompletedPulmonary SarcoidosisItaly
-
Daniel DobererTerminatedPulmonary Hypertension | SarcoidosisAustria
-
Ohio State UniversityThe Cleveland ClinicCompletedSarcoidosisUnited States
-
Ohio State UniversityTerminated
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
ShionogiCompleted
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Charles University, Czech RepublicCompleted
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
German Diabetes CenterYale UniversityEnrolling by invitationType2 DiabetesGermany
-
RenJi HospitalCompleted